Butane

Butane

SCHEMBL7716762

CCCC.O=C(O)CCP(=O)(O)O

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 1/20 0.50
HDAC3 O15379 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
FOLH1 Q04609 1/20 0.47
LPAR3 Q9UBY5 3/20 0.46
LPAR2 Q9HBW0 1/20 0.46
AKR1B1 P15121 1/20 0.44
GPR84 Q9NQS5 6/20 0.42
PPARG P37231 6/20 0.42
PPARD Q03181 6/20 0.42
PPARA Q07869 6/20 0.42
HDAC11 Q96DB2 5/20 0.42
TSHR P16473 4/20 0.42
ALDH1A1 P00352 2/20 0.42
TLR2 O60603 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
FABP4 P15090 2/20 0.42
PTPN1 P18031 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23648 0.89
Hexane SCHEMBL27503551 0.89 LPAR3 (0.58) LPAR3LPAR2AKR1B1GPR84PPARG
Water SCHEMBL28860761 0.87 FOLH1 (0.52) FOLH1TSHRALDH1A1TDP1MEN1
Hydrochloric Acid SCHEMBL28145400 0.87 FOLH1 (0.52) FOLH1TSHRALDH1A1TDP1MEN1
Ammonia Solution, Strong SCHEMBL28215144 0.87 FOLH1 (0.52) FOLH1TSHRALDH1A1TDP1MEN1
SCHEMBL11089864 0.87 FOLH1 (0.52) FOLH1TSHRALDH1A1TDP1MEN1
Decane SCHEMBL28743839 0.87 LPAR3 (0.61) LPAR3LPAR2AKR1B1GPR84PPARG
Butane SCHEMBL7718806 0.86 LPAR3 (0.54) LPAR3LPAR2AKR1B1GPR84PPARG
SCHEMBL18985374 0.85 FOLH1 (0.52) FOLH1TSHRALDH1A1TDP1MEN1
Benzene SCHEMBL28265143 0.84 FOLH1 (0.50) FOLH1TSHRALDH1A1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6376512-B1 FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-23 US disclosed
EP-0315399-B1 Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same RHONE POULENC RORER INT (US) 1996-01-10 EP disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed